To explore the effect of paternal perinatal depression, anxiety, and stress on offspring development from birth to 18 years, researchers conducted a systematic review and meta-analysis that synthesized the extant literature on this association.
Advertisement
Reduced-intensity HSCT conditioning with lentiviral gene therapy decreased severe vaso-occlusive events by more than 80%.
An interim analysis of the COMPLETE study found that pegcetacoplan improved indicators of blood health.
Kidney transplant candidates and their families often feel responsible but powerless during evaluation, a survey finds.
The protective effect of dog exposure early in life was seen in both cohort groups.
Use of SGLT2i with RAASi is associated with reduced risk for hyperkalemia in the clinical setting, a study found.
The SURPASS ET trial evaluated efficacy and safety of ropeginterferon alfa-2b in second-line ET treatment.
The low-FODMAP diet demonstrated superior reduction in IBS-SSS, but the Mediterranean diet also provided relief.
DocWire Content Partners
Powered by DocWire News
The Latest From GI Oncology Now
Suvemcitug, envafolimab, and FOLFIRI may serve as a new second-line treatment option for cold tumors.
KRASG12C inhibitors can have reduced efficacy in patients with alterations in KRAS, EGFR, and other genes.
Complete responders with HCC have prolonged survival and durable disease control even after therapy has been discontinued.
The primary objective of median PFS was significantly longer for patients treated with 177Lu-edotreotide.
The safety profile of the combination was consistent with known profiles, and no new safety findings were observed.
Older patients in their 70s with extrahepatic CCA have a higher rate of choledocholithiasis.
The Latest From Heme Today
Reduced-intensity HSCT conditioning with lentiviral gene therapy decreased severe vaso-occlusive events by more than 80%.
An interim analysis of the COMPLETE study found that pegcetacoplan improved indicators of blood health.
The SURPASS ET trial evaluated efficacy and safety of ropeginterferon alfa-2b in second-line ET treatment.
Data were presented at EHA2025 on the novel anti-CD38 monoclonal antibody CM313 for chronic ITP.
Evidence was presented at EHA2025 that the agent improves RBC health and blood flow in patients.